Abcellera Biologics Inc ABCL

$12.83 +0.75 (6.21%)

Valuation

Market cap
3,624,142,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,458,400
Avg volume
5,072,906
Day's range
$11.85 – $12.89
Shares out
306,611,000
Stochastic %K
97%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

erpy Oct 27, 11:00 PM
$ABCL Lets see it!
0 replies
VolumeSpreadAnalysis Oct 27, 9:36 PM
$ABCL Price: $12.83 Volume: Average or below Catalyst: Recent partnership/licensing updates around AbCellera's antibody discovery platform keep speculative interest alive despite no major pipeline readout. Resistance: $14.20 Support: $11.50 Bull case: A reclaim of $14.20 on rising volume could spark a squeeze back toward the mid-teens. Bear case: A breakdown below $11.50 with continued low volume signals exhaustion and risks a slide toward single digits. What I'm watching: Need volume to pick up alongside a close above resistance to confirm any real trend shift. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
Kaykay610 Oct 27, 6:16 PM
$ABCL ArsenalBio sheds most of staff in pivot to in vivo CAR-T https://share.google/GRJbYsW0uZcr5B88c
2 replies
teevee Oct 27, 5:41 PM
$ABCL ...
0 replies
StocksReportsX Oct 27, 4:28 PM
$ABCL had a good run, so a pullback isn’t too surprising. I’m watching $12 here. Would be good to see it settle above that and work its way back toward $14–$15. A weekly close below $11.80 would give me pause.
0 replies
sir_sip_a_lot Oct 27, 4:09 PM
$ABCL Part 1 AbCellera conferences are in November — **Stifel Healthcare Conference, November 11**, and **Jefferies Global Healthcare Conference in London, November 16**, with webcasts via AbCellera's IR site. The earnings call is **November 9**, after close. So the real cluster is Nov 9–16, not this week. My take on that cluster: **unlikely to drive the price up on its own.** Investor conferences are usually a recap and Q&A, not new data — and the October 22 release promised no new disclosure. The upside case needs a surprise. **Why the story is good:** - Phase 2 was genuinely strong: a single 600 mg dose cut hot flashes by 8.8/day vs 3.5 on placebo, a 5.3/day placebo-adjusted difference (p<0.001), 83% vs 33% reduction in frequency. - It was well tolerated, with no serious adverse events or discontinuations.
1 replies
sir_sip_a_lot Oct 27, 4:02 PM
$ABCL Part 3 **What would actually move it up** at Nov 9 or Nov 11: a concrete Phase 3 start date and design, FDA end-of-Phase-2 feedback, 12-week durability holding up, a confirmed monthly regimen, or a partnership. **What would hurt:** vague Phase 3 timing, a bigger/ pricier trial than expected, or durability fading. Base case for me: flat to choppy around the conferences, with a sharp move either way only if management says something genuinely new. That's analysis, not advice — and your Nov 9 morning reminder is still set.
0 replies
sir_sip_a_lot Oct 27, 4:02 PM
$ABCL Part 2 **Why that may already be priced in:** - The stock closed Monday at **$12.08**, down about 20% from its $15.02 52-week high, but still up 118% over the past year. Analyst targets average $16.82, so optimism is already baked in. - The big unknowns are still open: no Phase 3 design, trial count, or budget yet, and equity is the stated funding mechanism. Management itself said the top-line data is 4 weeks only, and the single-dose effect should diminish by week 12. - The trial was small — 92 women, 4 weeks — and comparisons to Veozah/Lynkuet are cross-trial, not head-to-head. Veozah carries a liver black-box warning and daily dosing, which is ABCL635's opening, but Phase 3 still has to prove durability over 12 weeks plus 52-week safety. - Last time around, the pattern was sell-the-news: down 7.1% on poster day Oct 22, then back up 4% Friday, with no bad news surfacing. The Cantor conference announcement in September was essentially flat.
0 replies